Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2.

MLA

Iwayama, Hideyuki, et al. “Long-Term Efficacy of Nusinersen and Its Evaluation in Adolescent and Adult Patients with Spinal Muscular Atrophy Types 1 and 2.” Brain & Development, vol. 45, no. 2, Feb. 2023, pp. 110–16. EBSCOhost, https://doi.org/10.1016/j.braindev.2022.10.006.

APA

Iwayama, H., Kawahara, K., Takagi, M., Numoto, S., Azuma, Y., Kurahashi, H., Yasue, Y., Kawajiri, H., Yanase, A., Ito, T., Kimura, S., Kumagai, T., & Okumura, A. (2023). Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2. Brain & Development, 45(2), 110–116. https://doi.org/10.1016/j.braindev.2022.10.006

Chicago

Iwayama, Hideyuki, Kohei Kawahara, Mizuki Takagi, Shingo Numoto, Yoshiteru Azuma, Hirokazu Kurahashi, Yumiko Yasue, et al. 2023. “Long-Term Efficacy of Nusinersen and Its Evaluation in Adolescent and Adult Patients with Spinal Muscular Atrophy Types 1 and 2.” Brain & Development 45 (2): 110–16. doi:10.1016/j.braindev.2022.10.006.